SpyGlass Pharma, Inc. SGP

SGP Company Overview

SpyGlass Pharma, Inc. (SGP) is a privately held ophthalmic biotechnology and drug-delivery company focused on developing therapies for chronic eye diseases, particularly glaucoma and other conditions that require sustained intraocular drug administration. The company operates within the ophthalmology, medical device, and pharmaceutical delivery sectors, combining implantable technologies with long-duration therapeutic delivery systems intended to reduce treatment burden and improve adherence for patients with chronic eye disorders.

The company’s primary focus has been the development of an intraocular lens-based drug delivery platform designed to provide sustained release of glaucoma medication following cataract surgery. SpyGlass Pharma emerged from advances in ophthalmic implant engineering and sustained-release pharmaceutical technologies, positioning itself at the intersection of cataract surgery and glaucoma management. Its strategic positioning is tied to addressing limitations associated with topical eye-drop adherence and the growing global prevalence of glaucoma and cataracts among aging populations.